

Yevgeniy R Semenov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5930653/publications.pdf>

Version: 2024-02-01

78
papers

1,765
citations

331259

21
h-index

329751

37
g-index

78
all docs

78
docs citations

78
times ranked

1932
citing authors

#	ARTICLE	IF	CITATIONS
1	A cross-sectional analysis of trends in dermatology practice size in the United States from 2012 to 2020. <i>Archives of Dermatological Research</i> , 2023, 315, 223-229.	1.1	4
2	Evaluating patterns of co-occurrence between cutaneous and noncutaneous immune-related adverse events after immune checkpoint inhibitor therapy. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 246-249.	0.6	2
3	Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1691-1695.	1.1	11
4	Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 563-572.	0.6	51
5	Health-related quality of life and economic burden of prurigo nodularis. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 573-580.	0.6	27
6	Racial and ethnic disparities in inpatient health care utilization for mycosis fungoides: A cross-sectional analysis of the 2012-2017 National Inpatient Sample. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1408-1410.	0.6	4
7	Racial disparities in mortality among patients with prurigo nodularis: A multi-center cohort study. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 487-490.	0.6	5
8	Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 252-255.	0.6	12
9	Validation of International Classification of Diseases Tenth Revision code for prurigo nodularis. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 482-484.	0.6	6
10	Cluster Analysis of Circulating Plasma Biomarkers in Prurigo Nodularis Reveals a Distinct Systemic Inflammatory Signature in African Americans. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1300-1308.e3.	0.3	21
11	Racial and socioeconomic differences in acral lentiginous melanoma outcomes: A Surveillance, Epidemiology, and End Results analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 866-867.	0.6	4
12	Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy. <i>JAMA Dermatology</i> , 2022, 158, 189.	2.0	60
13	Racial differences in dysregulation of the renin-angiotensin-aldosterone system in patients with prurigo nodularis. <i>Journal of Dermatological Science</i> , 2022, 105, 130-136.	1.0	8
14	Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1147-1149.	0.6	4
15	Pre-Existing Autoimmune Disease and Mortality in Patients Treated with Anti-PD-1 and Anti-PD-L1 Therapy. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1200-1202.	3.0	9
16	Latent class analysis identification of prurigo nodularis comorbidity phenotypes. <i>British Journal of Dermatology</i> , 2022, 186, 903-905.	1.4	5
17	Cutaneous Transcriptomics Identifies Fibroproliferative and Neurovascular Gene Dysregulation in Prurigo Nodularis Compared with Psoriasis and Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2537-2540.	0.3	18
18	Reply to: COVID-19 vaccination in IMID patients receiving rituximab: a personalized regimen should be formulated. <i>Journal of the American Academy of Dermatology</i> , 2022, , .	0.6	0

#	ARTICLE	IF	CITATIONS
19	Title: Immune-checkpoint inhibitor therapy is underutilized in the US: A multi-institutional cohort analysis. <i>Immunology Letters</i> , 2022, 244, 43-44.	1.1	0
20	Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors. <i>JAMA Dermatology</i> , 2022, 158, 552.	2.0	11
21	Reduced serum pyridoxine and 25-hydroxyvitamin D levels in adults with chronic pruritic dermatoses. <i>Archives of Dermatological Research</i> , 2022, , 1.	1.1	0
22	Understanding racial disparities in prurigo nodularis. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, e111-e112.	0.6	1
23	Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2896-2908.e4.	0.3	9
24	Risk of Hematologic Cancer in Patients With Undifferentiated Pruritus. <i>JAMA Dermatology</i> , 2022, 158, 791.	2.0	4
25	Health-related quality of life in patients with malignant melanoma by stage and treatment status. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 486-489.	0.6	2
26	Psoriasis and mortality in the United States: Data from the National Health and Nutrition Examination Survey. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 396-403.	0.6	39
27	Ethnic variations in scalp pruritus and hair loss. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 792-794.	0.6	3
28	Worldwide seasonal variation in search volume for cutaneous warts from 2004 to 2019. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1417-1419.	0.6	3
29	Current measures are not sufficient: an interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma*. <i>British Journal of Dermatology</i> , 2021, 184, 310-318.	1.4	13
30	Health-Related QOL and Economic Burden of Chronic Pruritus. <i>Journal of Investigative Dermatology</i> , 2021, 141, 754-760.e1.	0.3	33
31	Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. , 2021, 9, e001935.		38
32	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. <i>Oncologist</i> , 2021, 26, 514-522.	1.9	18
33	Surgical Outcomes and Risk Factors for Apical Triangle Basal Cell Carcinomas: A Single Institution Analysis. <i>Dermatologic Surgery</i> , 2021, 47, 1125-1127.	0.4	0
34	Biologics utilization for psoriasis is lower in black compared with white patients. <i>British Journal of Dermatology</i> , 2021, 185, 207-209.	1.4	10
35	Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2021, 26, e898-e901.	1.9	12
36	Patients with steroid-refractory toxicity following immune checkpoint inhibitors: Frequent hospitalizations and long duration of illness.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2655-2655.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Impact of cancer type on the incidence of cutaneous toxicities after immune checkpoint inhibitor therapy: A population-level analysis.. Journal of Clinical Oncology, 2021, 39, e14553-e14553.	0.8	0
38	Impact of multidisciplinary severe immunotherapy complication service on outcomes for cancer patients receiving immune checkpoint inhibition.. Journal of Clinical Oncology, 2021, 39, 2654-2654.	0.8	0
39	Itch in skin of colour: a multicentre cross-sectional study. British Journal of Dermatology, 2021, 185, 652-654.	1.4	9
40	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886.		9
41	Evolving phenotypes of non-hospitalized patients that indicate long COVID. BMC Medicine, 2021, 19, 249.	2.3	87
42	27645 Health-related quality of life and economic burden of prurigo nodularis. Journal of the American Academy of Dermatology, 2021, 85, AB38.	0.6	3
43	A Nationwide Study of Prurigo Nodularis: Disease Burden and Healthcare Utilization in the United States. Journal of Investigative Dermatology, 2021, 141, 2530-2533.e1.	0.3	17
44	Constructing germline research cohorts from the discarded reads of clinical tumor sequences. Genome Medicine, 2021, 13, 179.	3.6	25
45	804...Real-world incidence and impact of pneumonitis in lung cancer patients treated with immune checkpoint inhibitors. , 2021, 9, A841-A841.		0
46	An Observational Study on the Molecular Profiling of Primary Melanomas Reveals a Progression Dependence on Mitochondrial Activation. Cancers, 2021, 13, 6066.	1.7	4
47	Health-related quality of life and economic implications of cutaneous T-cell lymphoma. British Journal of Dermatology, 2020, 182, 190-196.	1.4	16
48	Clinical severity measures and quality of life burden in patients with mycosis fungoides and SÅ©zary syndrome: comparison of generic and dermatology-specific instruments. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 995-1003.	1.3	22
49	Association between vertigo, cognitive and psychiatric conditions in US children: 2012 National Health Interview Survey. International Journal of Pediatric Otorhinolaryngology, 2020, 130, 109802.	0.4	28
50	Comorbidities Associated with Granuloma Annulare: A Cross-Sectional, Case-Control Study. Medicines (Basel, Switzerland), 2020, 7, 53.	0.7	6
51	Diagnostic concordance of clinical diagnosis, tissue culture, and histopathology testing for skin and soft tissue infections: A single-center retrospective study. International Journal of Women's Dermatology, 2020, 6, 395-398.	1.1	1
52	Risk of cancer in psoriasis: study of a nationally representative sample of the US population with comparison to a single-institution cohort. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e529-e531.	1.3	2
53	855...Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses. , 2020, , .		0
54	Association between Itch and Cancer in 3836 Pediatric Pruritus Patients at a Tertiary Care Center. Medicines (Basel, Switzerland), 2019, 6, 99.	0.7	6

#	ARTICLE	IF	CITATIONS
55	Association Between Psoriasis with Arthritis and Hearing Impairment in US Adults: Data from the National Health and Nutrition Examination Survey. <i>Journal of Rheumatology</i> , 2019, 46, 587-594.	1.0	4
56	Racial Disparities in the Clinical Presentation and Prognosis of Patients with Mycosis Fungoides. <i>Journal of the National Medical Association</i> , 2019, 111, 633-639.	0.6	17
57	Proteomic and Phosphoproteomic Analysis Reveals that Neurokinin-1 Receptor (NK1R) Blockade with Aprepitant in Human Keratinocytes Activates a Distinct Subdomain of EGFR Signaling: Implications for the Anti-Pruritic Activity of NK1R Antagonists. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 114.	0.7	2
58	Health-related quality of life and economic burden of vestibular loss in older adults. <i>Laryngoscope Investigative Otolaryngology</i> , 2018, 3, 8-15.	0.6	44
59	Food and drug administration approval process for dermatology drugs in the United States. <i>Journal of Dermatological Treatment</i> , 2018, 29, 536-538.	1.1	3
60	Seasonality of hair loss: a time series analysis of Google Trends data 2004-2016. <i>British Journal of Dermatology</i> , 2018, 178, 978-979.	1.4	16
61	Racial disparities in the management of acne: evidence from the National Ambulatory Medical Care Survey, 2005-2014. <i>Journal of Dermatological Treatment</i> , 2018, 29, 287-289.	1.1	16
62	Ethnic differences and comorbidities of 909 prurigo nodularis patients. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 714-719.e3.	0.6	105
63	Seasonal variation of itch: A study using real-time data from 2004 to 2016. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 563-564.	0.6	8
64	Quality of Life and Cost-Effectiveness of Cochlear Implants: A Narrative Review. <i>Audiology and Neuro-Otology</i> , 2017, 22, 236-258.	0.6	58
65	Impaired Vestibular Function and Low Bone Mineral Density: Data from the Baltimore Longitudinal Study of Aging. <i>JARO - Journal of the Association for Research in Otolaryngology</i> , 2016, 17, 433-440.	0.9	8
66	Association Between Vestibular and Cognitive Function in U.S. Adults: Data From the National Health and Nutrition Examination Survey. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 243-250.	1.7	102
67	Vestibular vertigo and comorbid cognitive and psychiatric impairment: the 2008 National Health Interview Survey. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 367-372.	0.9	110
68	Vestibular Function and Activities of Daily Living. <i>Gerontology and Geriatric Medicine</i> , 2015, 1, 233372141560712.	0.8	41
69	Association Between Visuospatial Ability and Vestibular Function in the Baltimore Longitudinal Study of Aging. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 1837-1844.	1.3	100
70	The Role of Obliteration in the Achievement of a Dry Mastoid Bowl. <i>Otology and Neurotology</i> , 2015, 36, 1510-1517.	0.7	15
71	Bilateral Vestibular Deficiency. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 527.	1.2	118
72	Synchronous primary colorectal and liver metastasis: impact of operative approach on clinical outcomes and hospital charges. <i>Hpb</i> , 2014, 16, 1117-1126.	0.1	43

#	ARTICLE	IF	CITATIONS
73	Epidural Steroid Injections, Conservative Treatment, or Combination Treatment for Cervical Radicular Pain. <i>Anesthesiology</i> , 2014, 121, 1045-1055.	1.3	81
74	Age-Dependent Cost-Utility of Pediatric Cochlear Implantation. <i>Ear and Hearing</i> , 2013, 34, 402-412.	1.0	49
75	Postoperative Urinary Tract Infection and Short-Term Outcomes and Costs in Head and Neck Cancer Surgery. <i>Otolaryngology - Head and Neck Surgery</i> , 2013, 148, 602-610.	1.1	20
76	The effect of pneumonia on short-term outcomes and cost of care after head and neck cancer surgery. <i>Laryngoscope</i> , 2012, 122, 1994-2004.	1.1	55
77	The effect of deep venous thrombosis on short-term outcomes and cost of care after head and neck cancer surgery. <i>Laryngoscope</i> , 2012, 122, 2199-2204.	1.1	32
78	Cochlear Implants. <i>Otolaryngologic Clinics of North America</i> , 2012, 45, 959-981.	0.5	36